Application of fluorescence resonance energy transfer technology in cancer research / 医学研究生学报

In recent years , the emergence and progress of cancer genomics and targeted therapies have remarkably expanded the application fields of protein-protein interaction in cancer research .Fluorescence resonance energy transfer ( FRET ) is a kind of nonradiation energy transfer technique , which can timing , quantitative , positioning , and dynamically monitor the interaction between protein and protein in living cells .With the discovery of novel fluorescent proteins and the development of FRET -based biosensors , FRET has became an important method for visualizing spatial and temporal dynamics of interactions among biological macromolecules in native environments .This review summarises the recent studies and technological advances that have enhanced the use of FRET tech -nology in cancer basic research , early diagnosis , prognosis evaluation , drug development and other areas .

Detection of KRAS,NRAS and BRAF gene mutations in colorectal carcinoma / 中华病理学杂志

<p><b>OBJECTIVE</b>To investigate mutations frequencies of KRAS,NRAS and BRAF genes in colorectal carcinoma.</p><p><b>METHODS</b>Tissue specimens from 200 colorectal cancer patients at diagnosis were collected and subject to KRAS,NRAS and BRAF mutation analyses by PCR-based direct DNA sequencing targeting exons 2, 3 and 4 of KRAS gene, exons 2, 3 and 4 of NRAS gene and exon 15 of BRAF gene.</p><p><b>RESULTS</b>Activating mutations were detected in KRAS (44%, 88/200), NRAS (2%, 4/200) and BRAF (5%, 10/200) in this study cohort.Among KRAS mutations, 64.8% (57/88) occurred in codon 12 and 12.5% (11/88) occurred in codon 13. KRAS gene mutation in exon 3 mainly involved codons 59 and 61. KRAS gene mutation in exon 4 mainly involved codons 117 and 146.</p><p><b>CONCLUSIONS</b>Mutations at exon 2 of KRAS gene have the highest frequency in colorectal carcinoma. Expanding the detection sites of KRAS gene combined with NRAS and BRAF genes may help to identify patients who will most likely benefit from targeted therapies.</p>

Clinicopathologic analysis of HIV-negative plasmablastic lymphoma / 中华病理学杂志

<p><b>OBJECTIVE</b>To study the clinical, pathologic, immunophenotype, molecular characteristics and prognosis of HIV-negative plasmablastic lymphoma (PBL).</p><p><b>METHODS</b>Twelve cases of HIV-negative PBLs diagnosed between 2005 and 2014 in Guangdong General Hospital were identified according to WHO classification of tumors of haematopoietic and lymphoid tissues (2008). The clinicopathologic features and outcome were analyzed and the relevant literatures were reviewed.</p><p><b>RESULTS</b>The patients were predominantly male (11/12) with a median age of 55.5 years. The tumor cells showed the characteristic combination of immunoblastic/plasmablastic morphology, plasma cell phenotype and high proliferation, no expression of mature B cell markers. 7/10 of the cases were EBER positive. Two cases were positive for C-myc translocation. Four of twelve patients were died.</p><p><b>CONCLUSIONS</b>PBL is a rare, aggressive B-cell lymphoma. HIV-negative PBL has lower rate of oral involvement and EBER expression than HIV-positive patients, the differential diagnosis is very challenging, and the prognosis is worse.</p>